In order to enhance market competitiveness, w...

In order to enhance market competitiveness, we welcome any comments from consumers, favourable or _______.

A. rather B. regardless

C. otherwise D. though

高三英语单项填空困难题查看答案及解析

The severe competition in the job market has eventually ____ many students to the idea that knowledge plus ability is the only way out．

A． connected　 　　 　　 B． converted

C． confirmed　　　　 　 D． combined

高三英语单项填空中等难度题查看答案及解析

In order to gain a bigger share in the international market, many state companies are starving _______ their products more competitive.

A．making           B．to make           C．to have made      D．having made

高三英语单项填空简单题查看答案及解析

In order to keep fit, he chooses vegetables and fruit in ____to any kind of meat.

A．comparison        B．preference        C．control           D．advantage

高三英语单项填空中等难度题查看答案及解析

Is it only on the world market ________we can prove the competitiveness and quality of our goods?

A. where          B. which    C. that     D. how

高三英语单项填空中等难度题查看答案及解析

We all got up early_____we might start at six.

高三英语单项填空简单题查看答案及解析

“ New and improved. ” These words are put in so many marketing campaigns that we tend to accept them as linked. But many new drugs aren't an improvement over the best existing drug for a given condition, and the fast drug-approval processes in recent years have added to the uncertainty about their advantages.

A recent report in the British Medical Journal, "New Drugs: Where Did We Go Wrong and What Can We Do Better?, analysed the issue, The authors looked at 216 drugs approved between 2011 and 2017 ； 152 were newly developed, and 64 were existing medicine approved for new uses. Only 25% offered a major advantage over the established treatment, and fully 58% had no confirmed added benefit to reduce symptoms or improve health-related quality of life.

"This doesn’t mean there's no added benefit," lead author Wieseler said. “It just means we have no positive proof. Either we have no studies or have studies not good enough. ” Wieseler and her co-authors work for a German institute which evaluates new treatments and advises on whether the country's health care system should pay a premium ( 占)for them. Such organizations , known as health technology assessment ( HTA) agencies, work a little differently in the US, says Sean Tunis，a researcher in Baltimore: “ If payers think a new drug isn't better than an existing drug，these agencies will require .that hospitals try the cheaper drug first. ”

Germany's HTA demands trials to prove that a new treatment beats the existing standard. This isn't always practical For one thing, such studies can be expensive and time-consuming, with no guarantee of success. Secondly, it can discourage companies from attempting to develop new alternatives. This is already happening. Drug developers are increasingly focused on areas where there are no good treatments to compete with, such as rare diseases.

This lack of meaningful data to guide patients is a major point of Wieseler's paper- With accelerated approval, there are more products approved, with a greater amount of uncertainty about risks and benefits. But there are other solutions besides drug trials. One idea is to require postmarket studies to track the effectiveness of newly approved drugs—a step too often neglected.

1.What message does the recent report convey?

A.Many new drugs have no improved advantages.

B.The approval processes for new drugs are too fast.

C.Improved drugs have advantages over old ones.

D.Before 2017 no improvement was made to drugs.

2.What will US HTA agencies do when no advantage is found in new drugs?

A.Remove government premium on them.

B.Get hospitals to use the cheaper drugs.

C.Arrange financial support for the patients.

D.Put new drugs on further trials and studies.

3.What's the disadvantage of Germany's HTA trial demands?

A.Making drug companies think of illegal ways to cut cost.

B.Pushing companies to try alternatives for existing drugs.

C.Getting patients to depend on the government for support.

D.Holding companies back from improving existing drugs.

4.What is the best title for the text?

A.The Advantage of Existing Drugs

B.Misunderstanding of New and Old Drugs

C.A Dilemma with New Drug Alternatives

D.Peopled Preference for New or Old Drugs

高三英语阅读理解中等难度题查看答案及解析

＂New and improved."These words are put in so many marketing campaigns that we tend to accept them as linked.But many new drugs aren't an improvement over the best existing drug for a given condition,and the fast drug-approval processes in recent years have added to the uncertainty about their advantages.

A recent report in the British Medical Journal,"New Drugs;Where Did We Go Wrong and What We Do Better?" analyzed the issue,The authors looked at 216 drugs approved between 2011 and 2017; 152 were newly developed,and 64 were existing medicine approved for new uses. Only 25% offered a major advantage over the established treatment,and fully 58% had no confirmed added benefit to reduce symptoms or improve health-related quality of life.

＂This doesn't mean there's no added benefit,"lead author Wieseler said."It just means we have no positive proof Either we have no studies or have studies not good enough.”Wieseler and her co-authors work for a German agency which evaluates new treatments and advises on whether the country's health care system should pay a premium(补贴）for them.If payers think a new drug isn't better than an existing drug,these agencies will require that hospitals try the cheaper drug first.

Germany's HTA demands trials to prove that a new treatment beats the existing standard. This isn't always practical. For one thing, such studies can be expensive and time-consuming,with no guarantee of success.Secondly,it can discourage companies from attempting to develop new alternatives.This is already happening.Drug developers are increasingly focused on areas where there are no good treatments to compete with,such as rare diseases.

This lack of meaningful data to guide patients is a major point of Wieseler's paper.With accelerated approval,there are more products approved,with a greater amount of uncertainty about risks and benefits. But there are other solutions besides drug trials.One idea is to require postmarket studies to track the effectiveness of newly approved drugs-a step too often neglected.

1.What message does the recent report convey?

A.Improved drugs have advantages over old ones.

B.The approval processes for new drugs are too fast.

C.Many new drugs have no improved advantages.

D.Almost half the drugs approved target the special cases.

2.What's the disadvantage of Germany's HTA trial demands?

A.Making drug companies think of illegal ways to cut cost.

B.Holding companies back from improving existing drugs.

C.Getting patients to depend on the government for support.

D.Pushing companies to try alternatives for existing drugs.

3.What is the best title for the text?

A.The Advantage of Existing Drugs B.The Great Potential of New Drugs

C.People's Preference for New or Old Drugs D.A Dilemma with New Drug Alternatives

高三英语阅读理解中等难度题查看答案及解析

“New and improved. “These words are put in so many marketing campaigns that we tend to accept them as linked. But many new drugs aren’t an improvement over the best existing drug for a given condition, and the fast drug-approval processes in recent years have added to the uncertainty about their advantages.

A recent report in the British Medical Journal, “New Drugs: Where Did We Go Wrong and What Can We Do Better? “Analyzed the issue. The authors looked at 216 drugs approved between 2011 and 2017:152 were newly developed, and 64 were existing medicine approved for new uses. Only 25%offered a major advantage over the established treatment, and fully 58%had no confirmed added benefit to reduce symptoms or improve health-related quality of life.

“This doesn’t mean there’s no added benefit, “lead author Wissler said. “It just means we have no positive proof. Either we have no studies or have studies not good enough. “Wissler and her co-authors work for a German institute which evaluates new treatments and advises on whether the country’s health care system should pay a premium(补贴)for them. Such organizations, known as health technology assessment(HTA)agencies, work a little differently in the US, says Sean Tunisia researcher in Baltimore: “If payers think a new drug isn’t better than an existing drug, these agencies will require that hospitals try the cheaper drug first.”

Germanys HTA demands trials to prove that a new treatment beats the existing standard. This isn’t always practical. For one thing, such studies can be expensive and time-consuming, with no guarantee of success. Secondly, it can discourage companies from attempting to develop new alternatives. This is already happening. Drug developers are increasingly focused on areas where there are no good treatments to compete with, such as rare diseases.

This lack of meaningful data to guide patients is a major point of Wissler’s paper. With accelerated approval, there are more products approved, with a greater amount of uncertainty about risks and benefits. But there are other solutions besides drug trials. One idea is to require postmarked studies to track the effectiveness of newly approved drugs—a step too often neglected.

1.What message does the recent report convey?

A.Improved drugs have advantages over old ones.

B.Many new drugs have no improved advantages.

C.Before 2017 no improvement was made to drugs.

D.The approval processes for new drugs are too fast.

2.What will US HTA agencies do when no advantage is found in new drugs?

A.Get hospitals to use the cheaper drugs.

B.Remove government premium on them.

C.Arrange financial support for the patients.

D.Put new drugs on further trials and studies.

3.What’s the disadvantage of Germany’s HTA trial demands?

A.Getting patients to depend on the government for support.

B.Making drug companies think of illegal ways to cut cost.

C.Holding companies back from improving existing drugs.

D.Pushing companies to try alternatives for existing drugs.

4.What is the best title for the text?

A.The Advantage of Existing Drugs

B.A Dilemma with New Drug Alternatives

C.Misunderstanding of New and Old Drugs

D.People’s Preference for New or Old Drug

高三英语阅读理解困难题查看答案及解析

It’s really a tough job for automakers doing marketing and sales in China, where competition is acute and customers have little loyalty． They have tried a range of tricks in recent years．

But there should be a moral bottom line． Unfortunately, a Buick dealership used the tragedy of a two-month-old infant to advertise its cars last week on Weibo – Micro blog． And Hyundai Motor followed suit．

On March 4, an SUV was stolen with the infant left inside alone in the northeastern city of Changchun． The news spread widely on Weibo after the baby’s father called the local police and radio station for help． The next day it was revealed that the infant was choked to death and buried in snow by the thief． The online community expressed its deeply felt sympathy and condolences．

The Buick dealership posted a photo of the baby and two of its cars on its official Weibo account to advertise its GPS system that can locate the stolen car. “A few thoughts on the Changchun stolen car and baby incident: when buying a car it's entirely OK to choose a brand with advanced technology,” said the post. Though the post was made before tragic fate of the infant was known, the action generated a storm of outrage on Weibo. Some online commentators said it is “marketing at the cost of lives” and “extremely despicable.”

Worse was the post on Hyundai's off icial Weibo account that advertised the anti - theft system on its new SUV Santa Fe, an entry made after the child was known to have died. The action also enraged micro bloggers.

Both posts were soon deleted. The Buick dealership made an apology on Weibo to the family of the victim and the public. But screenshots saved by users continued to be posted and the negative impact on both brands persists.

The two brands probably didn’t expect such a firestorm of fury from the Internet community, but they really made a big mistake sinking below the moral bottom line． They certainly ruined their own brand images．

The Chinese have the same proverb as the English language – a little leak will sink a great ship． It takes decades to build the great ship of a respectable brand but it can take just a moment of negligence to make it fail completely．

For those in corporate marketing, two lessons should be learned: first, be careful in the era of social media when one wrong can be easily magnified and have disastrous impacts in just a few clicks．

Second and more importantly, think with your brain and heart． Never break the moral bonds of respect for human life and sympathy for our fellow man．

1.Who is to blame for the tragedy of Changchun infant according to the passage?

A．The baby’s father　　 B．Buick and Hyundai dealership

C．Weibo　　　　　　　　　　　 D．Not clear

2.Which of the following statements is correct?

A．The missing infant was found alive in the stolen car．

B．Micro blog marketing of tragic infant death fuels firestorm of criticism．

C．People can’t see the two posts any more because they were deleted．

D．The two car brands mentioned in the passage spoiled their own reputation by selling the stolen car．

3.What does the underlined word – “despicable” in paragraph 4 mean?

A．Immoral　　　　 　　 　 B．Important

C．Distinguished　　　　 D．Considerable

4.The reason why Hyundai’s post was worse than Buick’s is that _________．

A．Hyundai dealership didn’t make an apology on Weibo

B．Buick dealership expressed its deeply sympathy and condolences

C．Hyundai’s post was made after people knew the infant had died

D．Buick’s car was more advanced on its GPS system

5.In the last paragraph, the author encourages people _____________．

A．not to sink below the moral bottom line

B．not to sympathize our fellow man

C．to think twice before making decision

D．to magnify the mistakes people make

高三英语阅读理解中等难度题查看答案及解析